EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource‐limited settings: A randomized clinical trial

Farhad Abolhasan Choobdar iD, Peyman Shahhosseini iD, Zahra Vahedi iD, Nastaran Khosravi iD, Nasrin Khalesi iD, Maral Ghassemzadeh iD

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26451 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Farhad Abolhasan Choobdar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, School of Medicine, Subspecialty of Neonatal and perinatal medicine, Ali-Asghar Children's Hospital, Iran University of Med…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The standard treatment for persistent pulmonary hypertension of the newborn (PPHN) is inhaled nitric oxide (iNO), which is not available in Iran. Consequently, other drugs, such as milrinone, are prescribed. So far, no study has investigated the effectiveness of inhaled milrinone in the management of PPHN. The present study aimed to improve the management of PPHN in the absence of iNO.

Methods

In this randomized clinical trial, neonates with PPHN, admitted to the neonatal intensive care unit of Hazrat Ali‐Asghar and Akbar‐Abadi hospitals, were treated with intravenous dopamine infusion and randomly divided into two groups, receiving milrinone through inhalation or infusion rout. The neonates were evaluated by Doppler echocardiography, clinical examinations, and oxygen demand test. The neonates were also evaluated for the clinical symptoms and mortality in the follow‐up.

Results

A total of 31 infants, with a median age of 2 days (interquartile range = 4), were included in this study. There was a significant decrease in the peak systolic and mean pulmonary arterial pressure in both inhalation and infusion groups following milrinone administration, with no significant difference between the groups ( p = 0.584 and p = 0.147, respectively). There was no significant difference between the two groups regarding the mean systolic blood pressure before and after treatment. Additionally, diastolic blood pressure was significantly lower in the infusion group after treatment ( p = 0.020); however, the amount of reduction was not significantly different between the groups ( p = 0.928). Overall, 83.9% of the participants achieved full recovery, 75% of whom were in the infusion group and 93.3% in the inhalation group ( p = 0.186).

Conclusion

Milrinone inhalation can have similar effects to milrinone infusion as an adjunct treatment in the management of PPHN. Also, infusion and inhalation of milrinone showed similar safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryPersistent Fetal Circulation SyndromeInfant, NewbornHumansMilrinoneNitric OxideAdministration, Inhalation

Stichwörter der Autor:innen

neonatesoxygenationpersistent fetal circulation syndromepulmonary artery hypertensionrespiratory distress

Substanzen

MilrinoneNitric Oxide

Autor:innen und Institutionen

  • Department of Pediatrics, School of Medicine, Subspecialty of Neonatal and perinatal medicine, Ali-Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Pediatrics, School of Medicine, Ali-Asghar Children's Hospital, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Pediatrics, School of Medicine, Firouzabadi Hospital, Subspecialty of Neonatal and perinatal medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Pediatrics, School of Medicine, Hakim Children's Hospital, Subspecialty of Neonatal and perinatal medicine, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Farhad Abolhasan Choobdar, Peyman Shahhosseini, Zahra Vahedi, Nastaran Khosravi, Nasrin Khalesi, Maral Ghassemzadeh

Zitieren

APA

Choobdar, F. A., Shahhosseini, P., Vahedi, Z., Khosravi, N., Khalesi, N., & Ghassemzadeh, M. (2023). Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource‐limited settings: A randomized clinical trial. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26451

Vancouver

Choobdar FA, Shahhosseini P, Vahedi Z, Khosravi N, Khalesi N, Ghassemzadeh M. Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource‐limited settings: A randomized clinical trial. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26451

BibTeX
@article{Choobdar2023,
  author = {Choobdar, Farhad Abolhasan and Shahhosseini, Peyman and Vahedi, Zahra and Khosravi, Nastaran and Khalesi, Nasrin and Ghassemzadeh, Maral},
  title = {Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource‐limited settings: A randomized clinical trial},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26451}
}
Kostenlos starten →